CompletedNot Applicable

Biomarkers of AKI in Patients Receiving Daratumumab

United States20 participantsStarted 2024-09-01

Plain-language summary

The goal of this prospective observational study is to understand changes in urinary and blood biomarkers associated with acute kidney injury (AKI) in patients newly diagnosed with multiple myeloma and being treated with Daratumumab SC. The aims of the study are: To measure changes in plasma and urinary biomarkers of AKI before initiation of Daratumumab therapy and 30 days after initiation of therapy. To establish whether these biomarkers serve to aid in early detection and prevention of AKI Participants will give urine and blood samples at their normally scheduled lab appointments.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. New diagnosis of systemic multiple myeloma defined as no documented history of prior multiple myeloma.
✓. Further, no prior systemic treatment with anti-myeloma agent is permitted with the exception of corticosteroids for no more than 4 weeks.
✓. Prior history of receiving radiation therapy for the treatment of plasmacytoma or lytic lesions, is permitted on the study.

What they're measuring

Plasma and Urine Biomarkers

Timeframe: 30 days

Trial details

NCT IDNCT06549634

SponsorBrigham and Women's Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-01-15

View on ClinicalTrials.gov More Acute Kidney Injury trials